Rectal and colon cancer: Not just a different anatomic site

Cancer Treatment Reviews

Volumn 41, Issue 8, 2015, Pages 671-679

  Tamas, K ^a   Walenkamp, A M E ^a   de Vries, E G E ^a   van Vugt, M A T M ^a   Beets Tan, R G ^b   van Etten, B ^a   de Groot, D J A ^a   Hospers, G A P ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Epidemiology; Metastasis; Molecular markers; Rectal and colon cancer; Staging; Treatment

Indexed keywords

B RAF KINASE; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CTCE 9908; FLUOROURACIL; FOLINIC ACID; K RAS PROTEIN; LY 2510924; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; OXALIPLATIN; PLERIXAFOR; PROTEIN MLH1; UNCLASSIFIED DRUG; BRAF PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADENOCARCINOMA; ADJUVANT CHEMORADIOTHERAPY; ADJUVANT CHEMOTHERAPY; BODY MASS; CANCER LOCALIZATION; CANCER STAGING; COLON CANCER; COLORECTAL CANCER; DIET; GENE MUTATION; GENOMIC INSTABILITY; GLIOMA; HUMAN; LIVER METASTASIS; LUNG METASTASIS; METHYLATION; MUCINOUS ADENOCARCINOMA; MULTIPLE CYCLE TREATMENT; PHYSICAL ACTIVITY; RECTUM CANCER; REVIEW; SIGNET RING CARCINOMA; SMOKING; TUMOR MICROENVIRONMENT; ABDOMINAL SURGERY; COLONIC NEOPLASMS; DISEASE MANAGEMENT; GENETICS; METASTASIS; PATHOLOGY; PROCEDURES; RECTAL NEOPLASMS; SURVIVAL;

CHEMORADIOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; DIGESTIVE SYSTEM SURGICAL PROCEDURES; DISEASE MANAGEMENT; HUMANS; NEOPLASM METASTASIS; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECTAL NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84941024773     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2015.06.007     Document Type: Review

References (116)

1. Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015, 65:87-108.
2. Heald R.J., Moran B.J. Embryology and anatomy of the rectum. Semin Surg Oncol 1998, 15:66-71.
3. Iacopetta B. Are there two sides to colorectal cancer?. Int J Cancer 2002, 101:403-408.
4. Li F.Y., Lai M.D. Colorectal cancer, one entity or three. J Zhejiang Univ Sci B 2009, 10:219-229.
5. Kapiteijn E., Marijnen C.A., Nagtegaal I.D., Putter H., Steup W.H., Wiggers T., et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001, 345:638-646.
6. Sauer R., Becker H., Hohenberger W., Rödel C., Wittekind C., Fietkau R., et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004, 351:1731-1740.
7. Bosset J.F., Collette L., Calais G., Mineur L., Maingon P., Radosevic-Jelic L., et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006, 355:1114-1123. EORTC Radiotherapy Group Trial 22921.
8. Graham J.S., Cassidy J. Adjuvant therapy in colon cancer. Expert Rev Anticancer Ther 2012, 12:99-109.
9. (accessed 04-05-2015). https://www.adjuvantonline.com/.
10. Glimelius B., Tiret E., Cervantes A., Arnold D. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013, 24(suppl 6):681-688. ESMO Guidelines Working Group.
11. Rectal cancer NCCN Clinical Practice Guidelines in Oncology V.2.2015: (accessed 04-05-2015). http://www.nccn.org/professionals/physician_gls/PDF/rectal.pdf.
12. Colon cancer NCCN Clinical Practice Guidelines in Oncology V.2.2015: (accessed 04-05-2015). http://www.nccn.org/professionals/physician_gls/PDF/colon.pdf.
13. VanCutsem E., Cervantes A., Nordlinger B., Arnold D. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014, 25(suppl 3):31-39. ESMO Guidelines Working Group.
14. Dutch Comprehensive Cancer Centres: (accessed 04-05-2015). http://www.cancerregistry.nl.
15. Labianca R., Nordlinger B., Beretta G.D., Mosconi S., Mandalà M., Cervantes A., et al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013, 24(suppl 6):664-672.
16. Dutch National Working Group on Gastrointestinal Cancers. Guidelines rectal cancer: (accessed 04-05-2015). http://www.oncoline.nl.
17. Dutch National Working Group on Gastrointestinal Cancers. Guidelines colon cancer: (accessed 04-05-2015). http://www.oncoline.nl.
18. Cancer Research UK: (accessed 13-01-2015). http://www.cancerresearchuk.org/cancer-info/cancerstats/types/bowel/incidence/.
19. Greystoke A., Mullamitha S.A. How many diseases are colorectal cancer?. Gastroenterol Res Pract 2012, 2012:564741.
20. Cheng L., Eng C., Nieman L.Z., Kapadia A.S., Du X.L. Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005. Am J Clin Oncol 2011, 34:573-580.
21. Rhodes J.B., Holmes F.F., Clark G.M. Changing distribution of primary cancers in the large bowel. JAMA 1977, 238:1641-1643.
22. Ghahremani G.G., Dowlatshahi K. Colorectal carcinomas: diagnostic implications of their changing frequency and anatomic distribution. World J Surg 1989, 13:321-324.
23. Saltzstein S.L., Behling C.A. Age and time as factors in the left-to-right shift of the subsite of colorectal adenocarcinoma: a study of 213,383 cases from the California Cancer Registry. J Clin Gastroenterol 2007, 41:173-177.
24. Obrand D.I., Gordon P.H. Continued change in the distribution of colorectal carcinoma. Br J Surg 1998, 85:246-248.
25. Singh H., Demers A.A., Xue L., Turner D., Bernstein C.N. Time trends in colon cancer incidence and distribution and lower gastrointestinal endoscopy utilization in Manitoba. Am J Gastroenterol 2008, 103:1249-1256.
26. Miller A., Gorska M., Bassett M. Proximal shift of colorectal cancer in the Australian Capital Territory over 20 years. Aust N Z J Med 2000, 30:221-225.
27. Jass J.R. Subsite distribution and incidence of colorectal cancer in New Zealand, 1974-1983. Dis Colon Rectum 1991, 34:56-59.
28. Takada H., Ohsawa T., Iwamoto S., Yoshida R., Nakano M., Imada S., et al. Changing site distribution of colorectal cancer in Japan. Dis Colon Rectum 2002, 45:1249-1254.
29. Toyoda Y., Nakayama T., Ito Y., Ioka A., Tsukuma H. Trends in colorectal cancer incidence by subsite in Osaka, Japan. Jpn J Clin Oncol 2009, 39:189-191.
30. Levi F., Randimbison L., La Vecchia C. Trends in subsite distribution of colorectal cancers and polyps from the Vaud Cancer Registry. Cancer 1993, 72:46-50.
31. Thorn M., Bergstrom R., Kressner U., Sparén P., Zack M., Ekbom A. Trends in colorectal cancer incidence in Sweden 1959-93 by gender, localization, time period, and birth cohort. Cancer Causes Control 1998, 9:145-152.
32. Mitry E., Benhamiche A.M., Couillault C., Roy P., Faivre-Finn C., Clinard F., et al. Effect of age, period of diagnosis and birth cohort on large bowel cancer incidence in a well-defined French population, 1976-1995. Eur J Cancer Prev 2002, 11:529-534.
33. Scheiden R., Pescatore P., Wagener Y., Kieffer N., Capesius C. Colon cancer in Luxembourg: a national population-based data report, 1988-1998. BMC Cancer 2005, 5:52.
34. Jensen O.M. Different age and sex relationship for cancer of subsites of the large bowel. Br J Cancer 1984, 50:825-829.
35. Fleshner P., Slater G., Aufses A.H. Age and sex distribution of patients with colorectal cancer. Dis Colon Rectum 1989, 32:107-111.
36. Slattery M.L., Friedman G.D., Potter J.D., Edwards S., Caan B.J., Samowitz W. A description of age, sex, and site distributions of colon carcinoma in three geographic areas. Cancer 1996, 78:1666-1670.
37. Samad A.K., Taylor R.S., Marshall T., Chapman M.A. A meta-analysis of the association of physical activity with reduced risk of colorectal cancer. Colorectal Dis 2005, 7:204-213.
38. Harriss D.J., Atkinson G., Batterham A., George K., Cable N.T., Reilly T., et al. Lifestyle factors and colorectal cancer risk (2): a systematic review and meta-analysis of associations with leisure-time physical activity. Colorectal Dis 2009, 11:689-701. Colorectal Cancer, Lifestyle, Exercise and Research Group.
39. Wolin K.Y., Yan Y., Colditz G.A., Lee I.M. Physical activity and colon cancer prevention: a meta-analysis. Br J Cancer 2009, 100:611-616.
40. Doubeni C.A., Major J.M., Laiyemo A.O., Schootman M., Zauber A.G., Hollenbeck A.R., et al. Contribution of behavioral risk factors and obesity to socioeconomic differences in colorectal cancer incidence. J Natl Cancer Inst 2012, 104:1353-1362.
41. Hugen N., Van de Velde C.J., De Wilt J.H., Nagtegaal I.D. Metastatic pattern in colorectal cancer is strongly influenced by histological subtype. Ann Oncol 2014, 25:651-657.
42. Bertario L., Russo A., Sala P., Eboli M., Radice P., Presciuttini S., et al. Survival of patients with hereditary colorectal cancer: a comparison of HNPCC and colorectal cancer in FAP patients with sporadic colorectal cancer. Int J Cancer 1999, 80:183-187.
43. Stadler Z.K., Shia J., Goodman K.A., et al. Characterization of rectal cancer in patients with Lynch syndrome. J Clin Oncol 2013, 31(suppl 4):350. abstr.
44. Noffsinger A.E. Serrated polyps and colorectal cancer: new pathway to malignancy. Annu Rev Pathol 2009, 4:343-364.
45. Markowitz S.D., Bertagnolli M.M. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med 2009, 361:2449-2460.
46. Fearon E.R. Molecular genetics of colorectal cancer. Annu Rev Pathol 2011, 6:479-507.
47. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767.
48. Fodde R., Kuipers J., Rosenberg C., Smits R., Kielman M., Gaspar C., et al. Mutations in the APC tumour suppressor gene cause chromosomal instability. Nat Cell Biol 2001, 3:433-438.
49. Van Cutsem E., Kohne C.H., Hitre E., Zaluski J., Chang Chien C.R., Makhson A., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 360:1408-1417.
50. Hitchins M.P., Wong J.J., Suthers G., Suter C.M., Martin D.I., Hawkins N.J., et al. Inheritance of cancer-associated MLH1 germ-line epimutation. N Engl J Med 2007, 356:697-705.
51. Weisenberger D.J., Siegmund K.D., Campan M., Young J., Long T.I., Faasse M.A., et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006, 38:787-793.
52. Di Nicolantonio F., Martini M., Molinari F., Sartore-Bianchi A., Arena S., Saletti P., et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008, 26:5705-5712.
53. Young J., Simms L.A., Biden K.G., Wynter C., Whitehall V., Karamatic R., et al. Features of colorectal cancer with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis. Am J Pathol 2001, 159:2107-2116.
54. Kambara T., Simms L.A., Whitehall V.L., Spring K.J., Wynter C.V., Walsh M.D., et al. BRAF mutation is associated with DNA methylation in serrated polyposis and cancers of the colorectum. Gut 2004, 53:1137-1144.
55. Gallagher D.J., Smith J.D., Offit K., Stadler Z.K. Diagnosis hereditary colorectal cancer. Clin Colorectal Cancer 2010, 9:205-211.
56. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-337. Cancer Genome Atlas Network.
57. Goto T., Marusawa H., Chiba T. Landscape of genetic aberrations detected in human colorectal cancers. Gastroenterology 2013, 145:686-688.
58. Slattery M.L., Curtin K., Wolff R.K., Boucher K.M., Sweeney C., Edwards S., et al. A comparison of colon and rectal somatic DNA alterations. Dis Colon Rectum 2009, 52:1304-1311.
59. Ang P.W., Loh M., Liem N., Lim P.L., Grieu F., Vaithilingam A., et al. Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular features. BMC Cancer 2010, 10:227.
60. Minoo P., Zlobec I., Peterson M., Terracciano L., Lugli A. Characterization of rectal, proximal and distal colon cancers based on clinicopathological, molecular and protein profiles. Int J Oncol 2010, 37:707-718.
61. Van Engeland M., Derks S., Smits K.M., Meijer G.A., Hermann J.G. Colorectal cancer epigenetics: complex simplicity. J Clin Oncol 2011, 29:1382-1391.
62. Bufill J.A. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med 1990, 113:779-788.
63. Yamauchi M., Morikawa T., Kuchiba A., Imamura Y., Qian Z.R., Nishihara R., et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 2012, 61:847-854.
64. Missiaglia E., Jacobs B., D'Ario G., Di Narzo A.F., Soneson C., Budinska E., et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol 2014, 25:1995-2001.
65. Sanz-Pamplona R., Cordero D., Berenguer A., Lejbkowicz F., Rennert H., Salazar R., et al. Gene expression differences between colon and rectum tumors. Clin Cancer Res 2011, 17:7303-7312.
66. Sinicrope F.A., Shi Q., Smyrk T.C., Thibodeau S.N., Dienstmann R., Guinney J., et al. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology 2015, 148:88-99.
67. Dienstmann R., Guinney J., Delorenzi M., DeReynies A., Roepman P., Sadanandam A., et al. Colorectal Cancer Subtyping Consortium (CRCSC) identification of a consensus of molecular subtypes. J Clin Oncol 2014, 32(suppl 5):3511. abstr.
68. Michael-Robinson J.M., Biemer-Huttmann A., Purdie D.M., Walsh M.D., Simms L.A., Biden K.G., et al. Tumour infiltrating lymphocytes and apoptosis are independent features in colorectal cancer stratified according to microsatellite instability status. Gut 2001, 48:360-366.
69. Le D.T., Uram J.N., Wang H., Bartlett B.R., Kemberling H., Eyring A.D., et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015, [Epub ahead of print].
70. Chambers A.F., Groom A.C., MacDonald I.C. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002, 2:563-572.
71. Pihl E., Hughes E.S., McDermott F.T., Johnson W.R., Katrivessis H. Lung recurrence after curative surgery for colorectal cancer. Dis Colon Rectum 1987, 30:417-419.
72. Kim M.J., Lee H.S., Kim J.H., Kim Y.J., Kwon J.H., Lee J.O., et al. Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer. BMC Cancer 2012, 12:347.
73. Baas J.M., Krens L.L., Guchelaar H.J., Morreau H., Gelderblom H. Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review. Oncologist 2011, 16:1239-1249.
74. Frykholm G.J., Glimelius B., Påhlman L. Preoperative or postoperative irradiation in adenocarcinoma of the rectum: final treatment results of a randomized trial and an evaluation of late secondary effects. Dis Colon Rectum 1993, 36:654-672.
75. Ginsberg G.G., Ahmad N. Endoscopic ultrasound for rectal cancer. Vis Hum J Endosc 2003, 2:897.
76. Bipat S., Glas A.S., Slors F.J., Zwinderman A.H., Bossuyt P.M., Stoker J. Rectal cancer: local staging assessment of lymph node involvement with endoluminal US, CT, and MR-imaging-a meta-analysis. Radiology 2004, 232:773-783.
77. Nagtegaal I.D., Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer?. J Clin Oncol 2008, 26:303-312.
78. Beets-Tan R.G. Rectal cancer: review with emphasis on MR imaging. Radiology 2004, 232:335-346.
79. Lahaye M.J., Engelen S.M., Nelemans P.J., Beets G.L., Van de Velde C.J., Van Engelshoven J.M., et al. Imaging for predicting the risk factors-the circumferential margin and nodal disease-of local recurrence in rectal cancer: a meta-analysis. Semin Ultrasound CT MR 2005, 26:259-268.
80. MERCURY Study Group Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ 2006, 333:779.
81. Beets-Tan R.G., Beets G.L., Vliegen R.F., Kessels A.G., Van Boven H., De Bruine A., et al. Accuracy of magnetic resonance imaging in prediction of tumour-free resection margin in rectal cancer surgery. Lancet 2001, 357:497-504.
82. Taylor F.G., Quirke P., Heald R.J., Moran B., Blomqvist L., Swift I., et al. One millimeter is the safe cut-off for magnetic resonance imaging prediction of surgical margin status in rectal cancer. Br J Surg 2011, 98:872-879.
83. Wang C., Zhou Z., Wang Z., Zheng Y., Zhao G., Yu Y., et al. Patterns of neoplastic foci and lymph node micrometastasis within the mesorectum. Langenbecks Arch Surg 2005, 390:312-318.
84. Brown G., Richards C.J., Bourne M.W., Newcombe R.G., Radcliffe A.G., Dallimoare N.S., et al. Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison. Radiology 2003, 227:371-377.
85. Beets-Tan R.G., Lambregts D.M., Maas M., Bipat S., Barbaro B., Caseiro-Alves F., et al. Magnetic resonance imaging for the clinical management of rectal cancer patients: recommendations from the 2012 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. Eur Radiol 2013, 23:2522-2531.
86. Tudyka V., Blomqvist L., Beets-Tan R.G., Boelens P.G., Valentini V., Van de Velde C.J., et al. EURECCA consensus conference highlights about colon & rectal cancer multidisciplinary management: the radiology expert review. Eur J Surg Oncol 2014, 40:469-475.
87. Sargent D., Sobrero A., Grothey A., O'Connell M.J., Buyse M., Andre T., et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2009, 27:872-877.
88. André T., Iveson T., Labianca R., Meyerhardt J.A., Souglakos I., Yoshino T., et al. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: prospective combined analysis of phase III trials investigating duration of adjuvant therapy with the FOLFOX (FOLFOX4 or modified FOLFOX6) or XELOX (3 versus 6months) regimen for patients with stage III colon cancer trial design and current status. Curr Colorectal Cancer Rep 2013, 9:261-269. IDEA Steering Committee.
89. Tougeron D., Sickersen G., Lecomte T., Mouillet G., Trouilloud I., Coriat R., et al. Impact of adjuvant chemotherapy with 5-FU or FOLFOX in colon cancers with microsatellite instability An AGEO multicenter study. J Clin Oncol 2014, 32(suppl 5):3508. abstr.
90. Bujko K., Glynne-Jones R., Bujko M. Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomized trials. Ann Oncol 2010, 21:1743-1750.
91. Breugom A.J., Swets M., Bosset J.F., Collette L., Sainato A., Cionini L., et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol 2015, 16:200-207.
92. Bosset J.F., Calais G., Mineur L., Maingon P., Stojanovic-Rundic S., Bensadoun R.J., et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol 2014, 15:184-190.
93. Cionini L., Sainato A., De Paoli A., et al. Final results of randomized trial on adjuvant chemotherapy after preoperative chemoradiation in rectal cancer. Radiother Oncol 2010, 96(suppl 1):S113-S114. abstr.
94. Breugom A.J., van Gijn W., Muller E.W., Berglund A., Van den Broek C.B., Fokstuen T., et al. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. Ann Oncol 2015, 26:696-701. Cooperative Investigators of the Dutch Colorectal Cancer Group and the Nordic Gastrointestinal Tumour Adjuvant Therapy Group.
95. Glynne-Jones R., Counsell N., Quirke P., Mortensen N., Maraveyas A., Meadows H.M., et al. Chronicle: Results of a randomized phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomizing postoperative adjuvant capecitabine plus oxaliplatin (Xelox) versus control. Ann Oncol 2014, 25:1356-1362.
96. Hong Y.S., Nam B.H., Kim K.P., Kim J.E., Park S.J., Park Y.S., et al. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol 2014, 15:1245-1253.
97. Kirstein M.M., Lange A., Prenzler A., Manns M.P., Kubicka S., Vogel A. Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data. Oncologist 2014, 19:1156-1168.
98. Brule S.Y., Jonker D.J., Karapetis C.S., O'Callaghan C., Moore M., Wong R., et al. Location of colon cancer (right-sided [RC] versus left-sided [LC]) as a predictor of benefit from cetuximab (CET): NCIC CTG CO.17. J Clin Oncol 2013, 31(suppl):3528. abstr.
99. Von Einem J.C., Heinemann V., Von Weikersthal L.F., Vehling-Kaiser U., Stauch M., Hass H.G., et al. Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial. J Cancer Res Clin Oncol 2014, 140:1607-1614.
100. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
101. Boisen M.K., Johansen J.S., Dehlendorff C., Larsen J.S., Osterlind K., Hansen J., et al. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer. Ann Oncol 2013, 24:2554-2559.
102. Loupakis F., Yang D., Yau L., Feng S., Cremolini C., Zhang W., et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst 2015, 107:dju427.
103. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
104. Fyfe G.A., Hurwitz H., Fehrenbacher L., Cartwright T., Hainsworths J., Heim W., et al. Bevacizumab plus irinotecan/5-FU/leucovorin for treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patient subgroups. J Clin Oncol 2004, 22(suppl 14):3617. abstr.
105. Cunningham D., Lang I., Marcuello E., Lorusso V., Ocvirk J., Shin D.B., et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 2013, 14:1077-1085. AVEX study investigators.
106. Grothey A., Sugrue M.M., Purdie D.M., Dong W., Sargent D., Hedrick E., et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008, 26:5326-5334.
107. Domanska U.M., Kruizinga R.C., Nagengast W.B., Timmer-Bosscha H., Huls G., De Vries E.G., et al. A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer 2013, 49:219-230.
108. Kioi M., Vogel H., Schultz G., Hoffman R.M., Harsh G.R., Brown J.M. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 2010, 120:694-705.
109. Ou D., Chen C., Lin S., Hsu C.H., Lin L.I. Chemokine receptor expression profiles in nasopharyngeal carcinoma and their association with metastasis and radiotherapy. J Pathol 2006, 210:363-373.
110. Tamas K., Domanska U.M., van Dijk T.H., Timmer-Bosscha H., Havenga K., Karrenbeld A., et al. CXCR4 and CXCL12 expression in rectal tumors of stage IV patients before and after local radiotherapy and systemic neoadjuvant treatment. Curr Pharm Des 2015, 21:2276-2283.
111. Wong D., Kandagatla P., Korz W., Chinni S.R. Targeting CXCR4 with CTCE-9908 inhibits prostate tumor metastasis. BMC Urol 2014, 12-14.
112. Galsky M.D., Vogelzang N.J., Conkling P., Raddad E., Polzer J., Roberson S., et al. Phase I trial of LY2510924, a CXCR4 peptide antagonist, in patients with advanced cancer. Clin Cancer Res 2014, 20:3581-3588.
113. Nilsson P.J., Van Etten B., Hospers G.A., Påhlman L., Van de Velde C.J., Beets-Tan R.G., et al. Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer-the RAPIDO trial. BMC Cancer 2013, 13:279.
114. Beets-Tan R.G., Beets G.L. MRI for assessing and predicting response to neoadjuvant treatment in rectal cancer. Nat Rev Gastroenterol Hepatol 2014, 11:480-488.
115. Prahallad A., Sun C., Huang S., Di Nicolantonio F., Salazar R., Zecchin D., et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012, 483:100-103.
116. Kopetz S., Overman M.J., Chen K., Lucio-Eterovic A.K., Kee B.K., Fogelman D.R., et al. Mutation and copy number discordance in primary versus metastatic colorectal cancer (mCRC). J Clin Oncol 2014, 32(suppl 5):3509. abstr.